Genprex (FRA:2DE1) Inventories, Work In Process: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2DE1 Genprex Inc FRA:2DE1
35 GF Score
Price €3.96
! 1 Warning Sign
View Full Analysis

What is Genprex Inventories, Work In Process?

Genprex FRA:2DE1 35 Inventories, Work In Process is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:2DE1 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Genprex's work in process for the quarter that ended in Mar. 2026 was €0.00 Mil.

Genprex Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Genprex's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genprex Inventories, Work In Process Chart

Genprex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genprex Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2DE1
35GF Score
Genprex Inc FRA:2DE1
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genprex Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €0.00 Mil mean?
Genprex (FRA:2DE1) has a Inventories, Work In Process of €0.00 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Genprex and its competitors.
Is Genprex's Inventories, Work In Process too high?
Genprex's current Inventories, Work In Process is €0.00 Mil. Overall, Genprex has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Genprex's Inventories, Work In Process compare to MLEC and LIMN?
Genprex's Inventories, Work In Process of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Genprex and its competitors. Genprex's current Inventories, Work In Process is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genprex stock overvalued right now?
Genprex (FRA:2DE1) has a current Inventories, Work In Process of €0.00 Mil. The current Inventories, Work In Process is €0.00 Mil. Genprex's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Genprex (FRA:2DE1), the current Inventories, Work In Process is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genprex Business Description

Other Exchanges GNPX:USA0A8I:UK
Address 3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
35GF Score

Get the complete analysis for FRA:2DE1

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.96
Price